A 52-year-old man with chronic kidney disease (eGFR 25 mL/min/1.73 m²) is prescribed two antibiotics: Drug A (90% renal excretion, Vd 0.5 L/kg) and Drug B (10% renal excretion, Vd 3 L/kg). Which parameter best distinguishes the pharmacokinetic impact of renal impairment on these two drugs?

Question

Accepted Answer

C. Plasma half-life will increase significantly more for Drug A than Drug B. ## Renal Impairment: Differential Impact on Renally-Dependent vs. Hepatically-Metabolized Drugs

### Pathophysiology of Renal Impairment on Pharmacokinetics

When renal function declines, drugs dependent on renal elimination accumulate because clearance is reduced. The impact on half-life depends on the **fraction of total body clearance that is renal**.

### Half-Life Relationship

**Key Point:** Half-life is determined by the equation:
$$t_{1/2} = \frac{0.693 	imes V_d}{CL_{total}}$$

Where $CL_{total} = CL_{renal} + CL_{hepatic} + CL_{other}$

In renal impairment:
- **Drug A (90% renal excretion):** Renal clearance drops dramatically → total clearance falls → t_1/2 increases **markedly**
- **Drug B (10% renal excretion):** Renal clearance drops, but hepatic clearance remains intact → total clearance minimally affected → t_1/2 increases **minimally**

### Quantitative Comparison

| Parameter | Drug A (90% renal) | Drug B (10% renal) |
| --- | --- | --- |
| **Normal renal function** | CL_total ≈ CL_renal | CL_total ≈ CL_hepatic |
| **eGFR 25 (25% of normal)** | CL_total drops ~68% | CL_total drops ~2.5% |
| **Half-life change** | 2–3 fold increase | Minimal change |
| **Accumulation risk** | **HIGH** | Low |
| **Clinical example** | Aminoglycosides, ACE inhibitors | Warfarin, theophylline |

**High-Yield:** The **fraction of renal excretion** is the critical determinant of how much half-life changes in renal impairment. A drug with 90% renal excretion will see a much larger relative increase in t_1/2 than a drug with 10% renal excretion.

### Clinical Pearl
Aminoglycosides (>90% renal excretion) require aggressive dose reduction or interval extension in CKD to prevent nephrotoxicity and ototoxicity. Warfarin (hepatic metabolism, <5% renal excretion) requires no dose adjustment in renal impairment—only in hepatic disease.

### Why Vd Does Not Change

**Warning:** Volume of distribution is a property of drug distribution into tissues and is **independent of renal function**. Vd does not change in renal impairment unless the drug binds to uremic toxins or there is altered protein binding (rare). The half-life change is driven entirely by reduced clearance, not by Vd.

Answer

A. Hepatic clearance will be impaired equally in both drugs

Answer

B. Volume of distribution will decrease proportionally in both drugs

Answer

D. Oral bioavailability will increase equally for both drugs

A 52-year-old man with chronic kidney disease (eGFR 25 mL/min/1.73 m²) is prescribed two antibiotics: Drug A (90% renal excretion, Vd 0.5 L/kg) and Drug B (10% renal excretion, Vd 3 L/kg). Which parameter best distinguishes the pharmacokinetic impact of renal impairment on these two drugs?

Explanation

Renal Impairment: Differential Impact on Renally-Dependent vs. Hepatically-Metabolized Drugs

Pathophysiology of Renal Impairment on Pharmacokinetics

Half-Life Relationship

Quantitative Comparison

Clinical Pearl

Why Vd Does Not Change

Practice similar questions

Join our NEET PG community

Parameter	Drug A (90% renal)	Drug B (10% renal)
Normal renal function	CL_total ≈ CL_renal	CL_total ≈ CL_hepatic
eGFR 25 (25% of normal)	CL_total drops ~68%	CL_total drops ~2.5%
Half-life change	2–3 fold increase	Minimal change
Accumulation risk	HIGH	Low
Clinical example	Aminoglycosides, ACE inhibitors	Warfarin, theophylline